Showing 3591-3600 of 5559 results for "".
- Safety and Tolerability Update for LEO's Tralokinumabhttps://practicaldermatology.com/news/safety-and-tolerability-update-for-leos-tralokinumab-1/2460590/LEO Pharma’s tralokinumab is well tolerated when used as monotherapy or in combination therapy with the topical corticosteroid (TCS) mometasone furoate, according to a late-breaking data analysis presented online at European Academy of Dermatology and Ve
- Optical Coherence Tomography Plus AI Can Quickly and Accurately Monitor Hair Regrowthhttps://practicaldermatology.com/news/optical-coherence-tomography-plus-ai-can-quickly-and-accurately-monitor-hair-regrowth/2460564/Optical coherence tomography plus artificial intelligence methods can accurately and efficiently monitor hair growth therapies, suggests a
- Kerecis Scores DoD Grant to Develop, Test New Fish-skin Wound Treatment for Soldiershttps://practicaldermatology.com/news/kerecis-scores-dod-grant-to-develop-test-new-fish-skin-wound-treatment-for-soldiers/2460561/The U.S. Department of Defense (DoD) awarded a grant of almost $600,000 to Kerecis to test the company’s fish-skin technology to better stabilize battlefield wounds and provide a bacterial barrier for them during evacuation. The grant money will be disbursed to Kerecis over
- Topical PDE4 Inhibitor from Arcutis Shows Benefit in Seborrheic Dermatitishttps://practicaldermatology.com/news/topical-pde4-inhibitor-from-arcutis-shows-benefit-in-seborrheic-dermatitis/2460544/Positive topline data from a Phase 2 clinical trial suggest ARQ-154 (topical roflumilast foam) from Arcutis Biotherapeutics, Inc. is a potential treatment for seborrheic dermatitis. Study results show that roflumilast foam 0.3%
- Forte Biosciences, Inc. Announces First Patient Dosed in Study of FB-401 for the Treatment of Children and Adults With ADhttps://practicaldermatology.com/news/forte-biosciences-inc-announces-first-patient-dosed-in-study-of-fb-401-for-the-treatment-of-children-and-adults-with-ad/2460541/The first patient has been dosed in Forte Biosciences, Inc.’s clinical trial of FB-401 for the treatment of atopic dermatitis (AD). The multi-center, placebo controlled clinical trial of FB-401 is expected to enroll approximately 124 pediatric, adolescent and adult subjects aged 2
- Marketing Exec Lizette Williams Joins RealSelf’s Boardhttps://practicaldermatology.com/news/lizette-williams-global-head-of-vertical-solutions-marketing-at-facebook-joins-realselfs-board/2460540/Marketing and advertising executive Lizette Williams is the newest member of RealSelf’s Board of Directors. Ms. Williams serves as the Global Head of Vertical Solutions Marketing at Facebook. Prior to Facebook she has worked in major marketing roles at McDonald's, Kimberl
- Lilly Launches Digital Health Open Innovation Challenge to Help Transform AD Carehttps://practicaldermatology.com/news/lilly-launches-digital-health-open-innovation-challenge-to-help-transform-ad-care/2460529/Eli Lilly and Company is launching an open innovation challenge for individuals and teams across the United States to submit inspiring digital health solutions to help make life better for people living with atopic dermatitis. The challenge, "Transforming Atopic Der
- Dr. Doris Day Joins Nufabrx’s Ad Boardhttps://practicaldermatology.com/news/dr-doris-day-joins-nufabrxs-ad-board/2460523/New York City dermatologist Doris Day, MD is the newest member of Nufabrx’s advisory board. Nufabrx is an advanced textiles company that has developed a proprietary biomaterial platform that embeds active ingredients into fabrics to 
- Arena Pharmaceuticals Announces First Subject Dosed in Phase 2 Trial Evaluating Etrasimod in Alopecia Areatahttps://practicaldermatology.com/news/arena-pharmaceuticals-announces-first-subject-dosed-in-phase-2-trial-evaluating-etrasimod-in-alopecia-areata/2460515/The first subject has been dosed in
- Dr. Marilyn Liang Assumes SPD Presidencyhttps://practicaldermatology.com/news/dr-marilyn-liang-assumes-sdp-presidency/2460468/Marilyn Liang, MD is the new president of the